Leave no one behind: Optimal Care of all Patients with Haemophilia A
Background: Haemophilia is an inherited bleeding disorder due to failure of throm- bin generation resulting from clotting factor deficiency. In haemophilia A, the de- ficient factor is Factor VIII due to mutations in the F8 gene. In the past several decades, we have seen an unprecedented evolution o...
Saved in:
Published in | Jornal de Assistência Farmacêutica e Farmacoeconomia Vol. 1; no. s3 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia
14.12.2022
|
Online Access | Get full text |
Cover
Loading…
Summary: | Background: Haemophilia is an inherited bleeding disorder due to failure of throm- bin generation resulting from clotting factor deficiency. In haemophilia A, the de- ficient factor is Factor VIII due to mutations in the F8 gene. In the past several decades, we have seen an unprecedented evolution of therapies for managing hae- mophilia A (Mahlangu, 2022) . These have included blood and blood products to plasma-derived concentrate, recombinant concentrate, concentrate with improved pharmacokinetics and, more recently, non-replacement therapies. Notwithstanding these advances in treatments, patients with haemophilia A (PwHA) remain with several unmet needs. |
---|---|
ISSN: | 2525-5010 2525-7323 |
DOI: | 10.22563/2525-7323.2022.v1.s3.4-7 |